Cosio, Borja GShafiek, HanaaToledo-Pons, NuriaIglesias, AmandaBarcelo, MargalidaRepresas-Represas, CristinaComeche, LorenaCatalan, PabloFernandez-Villar, AlbertoLopez-Campos, Jose LuisEchave-Sustaeta, JoseSoler-Cataluna, Juan Jose2023-02-092023-02-092021-06-03http://hdl.handle.net/10668/17987Exacerbations of COPD (ECOPD) are a frequent cause of hospitalization that seemed to ameliorate during the COVID outbreak. We aimed to evaluate the clinical characteristics of COPD-related hospital admissions and mortality in relation to the presence of COVID-19. We conducted a case-control study of patients admitted in four teaching hospitals throughout Spain between March 15 and April 30, 2020. Hospital admissions of respiratory cause with and without PCR-proven SARS-CoV-2 infection in patients with COPD were evaluated. Baseline and episode-related clinical characteristics were analyzed. Logistic regression analysis was performed to evaluate the risk for mortality. During the study period, 2101 patients were admitted for respiratory worsening, 1200 (57.1%) with COVID-19. A total of 228 (10.8%) were admitted due to COPD worsening, of whom 52 (22.8%) tested positive for COVID-19. COPD patients with COVID-19, when compared to those without COVID-19, were more frequently males with better lung function (FEV1 postbronchodilator 71% vs 46% respectively, p Hospitalizations for ECOPD without COVID-19 were more frequent than COPD with COVID-19 during the first outbreak, but the latter were associated with higher mortality and low eosinophil counts that warrant further analysis.enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/COPD exacerbationhospitalizationinhaled corticosteroidsmortalityCOVID-19Case-Control StudiesDisease OutbreaksHospitalizationHumansMalePulmonary Disease, Chronic ObstructiveSARS-CoV-2Spainresearch article34113088open access10.2147/COPD.S3124931178-2005PMC8184145https://www.dovepress.com/getfile.php?fileID=70196https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184145/pdf